Pharmacokinetics and pharmacodynamics of argatroban as studied by HPLC and functional methods: Implications in the monitoring and dosage- optimizations in cardiovascular patients

Clinical and Applied Thrombosis/Hemostasis

Volumn 4, Issue 4, 1998, Pages 243-249

  Ahmad, Sarfraz ^a   Ahsan, Ahmad ^a   Iqbal, Omer ^a   Hoppensteadt, Debra A ^a   Lewis, Bruce E ^a   Walenga, Jeanine M ^a   Fareed, Jawed ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antithrombin drugs; Argatroban; Heparin induced thrombocytopenia; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ARGATROBAN; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; ATHERECTOMY; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEPARINIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031664381     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969800400405     Document Type: Article

References (15)

1. Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996;7:455.
2. Banner DW, Hadvary P, Crystallographic analysis at 3.0-A○ resolution of the binding to human thrombin of four active-site directed inhibitors. J Biol Chem 1991;266:20085.
3. Bode W, Turk D, Sturzebecher J. Geometry of binding of the benzamadine-and arginine-based inhibitors N-alpha-(2-naphthyl-sulphony-glycy])-DL-p-amidinophenylalanyl-piperidine (NAPAP) and (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8-quinoline-sulfonyl)-L-arginyl]-2- piperidinecarboxylic acid (MQPA) to human alpha/thrombin. X-ray Crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur J Biochem 1990;193:175.
4. Okamoto S, Hijikata A, Kikimoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivatives No. 805. The importance of stereo structure of its hydrophobic carhoxamide portion. Biochem Biophys Res Commun 1981;101:440.
5. Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog and hirudin. Semin Thromb Hemost 1995;21:177.
6. Nowak G, Buch E. A new method for the therapeutic monitoring of hirudin. Thromb Haemost 1993;96:A1306.
7. Berry CN, Girard D, Lochot S, Lecoflre C. Antirhromnotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transaction bleeding time. Br J Pharmacol 1994;113:1209.
8. Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothclial injury. J Clin Invest 1989;84:18.
9. Jang IK, Gold HK, Ziskind AA, et al. Prevention of platelet-rich thrombosis by selective thrombin inhibition. Circulation 1990;81: 219.
10. Kurnada T, Abiko Y. Comparative study of heparin and a synthetic thrombin inhibitor No 805 (MD-805) in experimental antithrombin III-deficient animals. Thromb Res 1981;24:185.
11. 2 in reocclusion following coronay thrombolysis with tissue-type. Proc Natl Acad Sci USA 1989;86:7585.
12. Kawai H, Yamamoto T, Hara H, Tamao Y. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban. Thromb Res 1994;74:185.
13. Clarke RJ, Mayo G, Fitzgerald GA, Fitzgeral DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83:1510.
14. Ahmad S, Ahsan A, Iqbal O, Walenga JM, Lewis BE, Fareed J. Studies on biochemical and pharmacological properties of argatroban in man: Potential clinical implications. In: Savage LM, Thibeault CA eds. Anticoagulant, antithrombotic, and thrombalytic therapeutics II. Southborough, MA: IBC Library Series No. 1924, 1998;233.
15. Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent in patients with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 1998;49:61.